格雷夫斯甲状腺功能障碍治疗对脂质样本和胆固醇动态的影响:一项前性观察研究
Tomoko Nagamine1, Kyoko Tanimura-Inagaki1, Mototsugu Nagao2
1Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Therapeutic advances in endocrinology and metabolism
|September 12, 2025
概括
格雷夫斯的甲状腺功能障碍治疗通过促进胆固醇的合成和吸收,显著提高胆固醇水平. 这种脂质新陈代谢转变可能是由增加的蛋白转化酶亚素/素9型 (PCSK9) 水平驱动的.
科学领域:
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
- 脂质学 脂质学是指脂质学.
背景情况:
- 格雷夫斯的甲状腺功能障碍治疗对脂质代谢的影响尚不清楚.
- 这项研究调查了治疗后脂质谱和相关代谢途径的变化.
研究的目的:
- 为了澄清格雷夫斯的甲状腺功能障碍治疗如何影响脂质代谢.
- 检查胆固醇合成,吸收和低密度脂蛋白 (LDL) 受体调节的变化.
主要方法:
- 对17名新诊断的Graves甲状腺功能障碍患者进行前性观察研究.
- 血清脂质,阿波利波蛋白,非胆固醇固醇,PCSK9和LPL的测量在基线和6个月后的甲状腺状况.
主要成果:
- 总胆固醇,LDL胆固醇 (LDL-C) 和HDL胆固醇 (HDL-C) 在治疗后迅速增加;甘油三水平稍后增加.
- 胆固醇合成和吸收标志物 (拉索醇,醇,坎普醇,胆固醇) 显著增加.
- 循环PCSK9水平显著上升并保持高位,而脂蛋白脂酶 (LPL) 水平没有显著变化.
结论:
- 格雷夫斯的甲状腺功能障碍治疗导致胆固醇水平迅速增加.
- 增强胆固醇的合成和吸收是关键机制.
- 循环PCSK9的增加可能会调解这些脂质变化.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Synthesis and Regulation of Thyroid Hormones
7.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.2K
Blood Studies for Cardiovascular System III: Serum Lipid Profile
560
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
560
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185


